Transfection Reagents for Cell & Gene Therapy – Competitive Landscape & Demand Outlook

  • Private Equity
  • Healthcare
  • Europe


Former VP at Thermo Fisher Scientific Inc


  • Value proposition and utility of transfection reagents such as PEI (polyethylenimine) in C&GT (cell and gene therapy) workflows including in the manufacturing of viral vectors and in the transfection of cells
  • Pros and cons of chemical transfection vs other transfection or transduction technologies including electroporation, LNPs (lipid nanoparticles), microfluidics and viral vectors
  • Different types of transfection reagents and competitive positioning of incumbents including Polyplus, Polysciences, Mirus Bio, Thermo Fisher (NYSE: TMO) and Promega
  • Demand outlook for transfection reagents and TAM expansion opportunities


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited